Constangy Clips Ep. 10 - 3 Ways the GDPR Is Evolving with Today’s Tech Landscape
The Privacy Insider Podcast Episode 14: The Pig Around the Corner: Privacy and Trade with Constantine Karbaliotis of nNovation LLP
No Password Required: Founder of Cybersafe Foundation and an Obama Foundation Africa Leaders Fellow, Who Is Comfortable in the API Kitchen
Will the U.S. Have a GDPR? With Rachael Ormiston of Osano
Compliance with the New EU-US Data Privacy Framework
Life With GDPR - Data Transfer Update
Anonymization and AI: Critical Technologies for Moving eDiscovery Data Across Borders
Digital Trade: Key Trends and Developments to Watch
NGE On Demand: Personal Data Protection Travels: The New Standard Contractual Clause with John Koenigsknecht and David Wheeler
I Wish I Knew What I Know Now: Conversations with AGG on FDA Issues - Data Privacy Issues Life Sciences Companies May Encounter
In-house Roundhouse: Antitrust and the Tech Industry
Cross-Border Data Transfers and the EU-US Data Privacy Tug of War
Privacy Talk | The New Swiss Data Protection Act
Compliance Perspectives: The Privacy and Data Security Track at the 2020 Compliance & Ethics Institute
Update on Global Data Privacy Regulations by John Jackson
Nota Bene Episode 93: Navigating the New Global Cybersecurity Compliance Landscape with Scott Giordano
What's Next after the Schrems II Decision of ECJ
Compliance Perspectives: The End of the Privacy Shield
Nota Bene Episode 89: European Q3 Check In - Merger Clearance and Data Protection Court Rulings and Brexit Updates with Oliver Heinisch
IAPP Global Privacy Summit Recap, Big Questions, and Indiana Jones Analogies
With the continuing cuts to US Food and Drug Administration (FDA) staffing, the pharmaceutical and biotechnology industries are communicating increasing concern about potential product development impacts. While these cuts...more
Sovereign Wealth Fund Investment in the Global Healthcare Industry - Sovereign Wealth Funds (SWF) seek out investments that are resilient, conducive to their aims and objectives, and reasonably free from market...more
With the recent ruling that the Safe Harbor programme is invalid under European law, life sciences companies will need to review their strategies when exporting patient data to the United States....more